Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Humeau Laurent

2. Date of Event Requiring Statement (MM/DD/YYYY) 3/8/2019

3. Issuer Name and Ticker or Trading Symbol

INOVIO PHARMACEUTICALS, INC. [INO]

(Last) (First) (Middle)

C/O INOVIO PHARMACEUTICALS, INC., 6769 MESA RIDGE RD.

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Scientific Officer /

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	22201	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Unit	⁽¹⁾	3/8/2029 ⁽¹⁾	Common Stock	2666.0	⁽¹⁾	D
Restricted Stock Unit	⁽²⁾	3/10/2027 ⁽²⁾	Common Stock	5624.0	⁽²⁾	D
Restricted Stock Unit	⁽³⁾	3/5/2028	Common Stock	53133.0	⁽³⁾	D
Common Stock Option	⁽⁴⁾	1/6/2024	Common Stock	20000.0	$10.0	D
Common Stock Option	⁽⁴⁾	3/5/2025	Common Stock	25000.0	$7.56	D
Common Stock Option	⁽⁴⁾	3/9/2026	Common Stock	18000.0	$7.02	D
Common Stock Option	⁽⁴⁾	3/10/2027	Common Stock	13750.0	$6.68	D
Common Stock Option	⁽⁴⁾	3/5/2018	Common Stock	126500.0	$4.29	D

Explanation of Responses:
(1)	Each restricted stock unit represents a contingent right to receive one share of common stock. The 2,666 restricted stock vested on March 9, 2019.
(2)	Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,624 restricted stock units is as follows: 2,812 shares vested on March 10, 2019; 2,812 shares will vest on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
(3)	Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,133 restricted stock units is as follows: 26,567 shares will vest on March 5, 2020; 26,566 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
(4)	The common stock options will vest over a period of three years, with 25% of the shares underlying the option vesting immediately, and 25% on the first, second, and third anniversaries of the date of grant. The expiration date of this option reported in the table is the day of the tenth anniversary of the grant date of the option.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Humeau Laurent C/O INOVIO PHARMACEUTICALS, INC. 6769 MESA RIDGE RD. SAN DIEGO, CA 92121			Chief Scientific Officer

Signatures
/s/ Laurent Humeau		3/12/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.